Recent major‐researches‐advancements have significantly expanded our understanding of psoriasis‐pathophysiology, resulting in the development of highly effective targeted‐therapies, such as anti TNFα, IL‐12/23‐inhibitors, IL‐17‐inhibitors, or IL‐23‐inhibitors. The gene discussed is IL17A; the disease is psoriasis.